Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...
Key Takeaways Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...
Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...
Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, ...
Eli Lilly (LLY) stock in focus as the company expands Zepbound offerings with new vial formats at discounted prices. Read ...
6hon MSN
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound. For many consumers, their insurance denies them ...
Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...
Joe Nadglowski, president and CEO of the Obesity Action Coalition (OAC), appreciated Lilly's efforts to make obesity ...
(Reuters) - Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results